Phreesia Form 144 Discloses 93-Share Sale; Recent Insider Sales Listed
Rhea-AI Filing Summary
Phreesia, Inc. (PHR) filed a Form 144 reporting a proposed sale of 93 common shares through Fidelity Brokerage Services with an aggregate market value of $2,226.29, slated for 09/18/2025. The filing shows those 93 shares were acquired by restricted stock vesting on 09/15/2025 (35 shares) and 09/16/2025 (58 shares) and were received as compensation. The issuer has 59,914,473 shares outstanding, so the proposed sale represents a de minimis fraction of the outstanding stock. The filing also lists multiple insider sales over the past three months, including larger transactions by David Linetsky (e.g., 23,729 shares on 06/27/2025 for $676,195.48). The notice includes the standard signer representations about absence of undisclosed material information.
Positive
- Clear disclosure of acquisition dates, nature of acquisition (restricted stock vesting), broker, and proposed sale details
- Proposed sale size is de minimis relative to total shares outstanding (93 shares vs. 59,914,473 outstanding)
- Past sales are itemized, providing transparency about recent insider transactions including dates and gross proceeds
Negative
- Insider selling activity in the past three months includes larger disposals (e.g., 23,729 shares on 06/27/2025 for $676,195.48), which may warrant investor attention
- No statement of a 10b5-1 trading plan date is provided in the remarks, so it is unclear whether the sales are pre-planned
Insights
TL;DR: Small proposed sale (93 shares, $2,226) from recently vested restricted stock; not material to capitalization but follows notable insider selling this year.
The Form 144 reports a routine sale of vested restricted shares that were acquired as compensation on 09/15/2025 and 09/16/2025. At 93 shares and $2,226 aggregate value against 59.9 million shares outstanding, this notice is immaterial to Phreesia's market capitalization. However, the filing should be read alongside disclosed insider disposals in the prior three months, notably a 23,729-share sale on 06/27/2025, which indicates ongoing insider liquidity events that investors may want to contextualize with trading plans and federal exemptions.
TL;DR: Filing appears procedurally correct and includes signer representation; ensure timing aligns with Rule 144 requirements and any 10b5-1 plans.
The Form 144 furnishes acquisition dates, nature of acquisition (restricted stock vesting), broker details, and recent sale history, matching disclosure expectations. The filer attests to no undisclosed material information. From a compliance perspective, the close proximity of vesting and proposed sale dates is permissible but should be verified against any company blackout periods or pre-existing Rule 10b5-1 arrangements. No explicit plan dates are included in the remarks.